These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 5936513)

  • 21. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Long-term follow-up of consumption of plasma, blood and antihemophilic globulin in patients with hemophilia].
    Pudlák P; Horák J
    Vnitr Lek; 1968 Jan; 15(1):1-8. PubMed ID: 5720983
    [No Abstract]   [Full Text] [Related]  

  • 23. [Cellular immunology status in 5 hemophilic patients with inhibitors subjected to massive therapy with factor VIII concentrate].
    Aznar JA; Jorquera JI; González Molina A; Carbonell F; Trenor A; Sánchez Cuenca JM; de Andrés R
    Sangre (Barc); 1983; 28(5):663-4. PubMed ID: 6420915
    [No Abstract]   [Full Text] [Related]  

  • 24. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system.
    Pool JG; Shannon AE
    N Engl J Med; 1965 Dec; 273(27):1443-7. PubMed ID: 5852902
    [No Abstract]   [Full Text] [Related]  

  • 25. Topical application of antihemophilic factor after dental extractions in hemophilic patients.
    Nakajima T; Tomizawa M; Hasegawa S; Ohnishi M; Tokiwa N
    J Oral Surg; 1978 Nov; 36(11):873-7. PubMed ID: 280664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preparation of and clinical experience with antihemophilic factor concentrates.
    Johnson AJ; Karpatkin MH; Newman J
    Thromb Diath Haemorrh Suppl; 1968; 35():49-59. PubMed ID: 5317364
    [No Abstract]   [Full Text] [Related]  

  • 27. Surgery in haemophilia patients.
    Kwa SB
    Singapore Med J; 1968 Mar; 9(1):7-11. PubMed ID: 5659894
    [No Abstract]   [Full Text] [Related]  

  • 28. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII).
    Goldsmith JC
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgical management of the patient with classical hemophilia.
    Croom RD; Hutchin P
    Surg Gynecol Obstet; 1969 Apr; 128(4):793-800. PubMed ID: 4887342
    [No Abstract]   [Full Text] [Related]  

  • 30. Moynihan Lecture, 1980. Major surgery in haemophilia.
    Rudowski WJ
    Ann R Coll Surg Engl; 1981 Mar; 63(2):111-7. PubMed ID: 6787973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the lymphocyte in antihemophilic globulin production: a rise in antihemophilic globulin levels in a hemophilic subject with acute lymphoblastic leukemia.
    Bouhasin JD; Monteleone P; Altay C
    J Lab Clin Med; 1971 Jul; 78(1):122-9. PubMed ID: 5285069
    [No Abstract]   [Full Text] [Related]  

  • 32. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
    Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycine-precipitated antihemophilic factor concentrates and their clinical use.
    Wagner RH; Roberts HR; Webster WP; Shanbrom E; Brinkhous KM
    Thromb Diath Haemorrh Suppl; 1968; 35():41-8. PubMed ID: 5761073
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunological studies of haemophilic patients with inhibitors treated with Factor VIII concentrates in a protocol to induce immunotolerance.
    Aznar JA; Jorquera JI; Carbonell F; Sánchez-Cuenca JM; Trenor A; De Andrés Medina R; Carmona E; González-Molina A
    Thromb Haemost; 1984 Oct; 52(2):212-3. PubMed ID: 6441305
    [No Abstract]   [Full Text] [Related]  

  • 35. Aspects of the management of hemophilia in childhood. Availability of newer concentrates of antihemophilic factor failitates management.
    Strauss HS
    R I Med J; 1966 Aug; 49(8):466-8. PubMed ID: 5222119
    [No Abstract]   [Full Text] [Related]  

  • 36. [Use of antihemophilic fractions of animal origin in hemophilia: hemostatic effectiveness and immunological consequences].
    Goudend M; Delmas-Marsalet Y; Parquet-Gernez A; Lerche-Habart B
    Presse Med (1893); 1968 Jan; 76(5):197-200. PubMed ID: 5688999
    [No Abstract]   [Full Text] [Related]  

  • 37. Hemofil and other factor VIII concentrates.
    Med Lett Drugs Ther; 1969 Nov; 11(23):96. PubMed ID: 5375104
    [No Abstract]   [Full Text] [Related]  

  • 38. Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion.
    Morfini M; Messori A; Longo G
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S11-4. PubMed ID: 8735791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival of transfused factor VIII in hemophilic patients treated with epsilon aminocaproic acid.
    Weiss AE; Webster WP; Strike LE; Brinkhous KM
    Transfusion; 1976; 16(3):209-14. PubMed ID: 936268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Preparation of the antihemophilic cryoprotein from the acidified plasma. I].
    Vlcková M; Vopatová M
    Vnitr Lek; 1972 Aug; 18(8):795-800. PubMed ID: 5054177
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.